정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 527 | Recruiting | SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding | SARS-CoV 2 | Drug: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse | Early Phase 1 | University of Wisconsin, Madison | OTHER | 250 | All | 18 Years | University of Wisconsin-Madison, Madison, Wisconsin, United States |
| 526 | Completed | Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis | Covid19 | Drug: 20 Mg Prednisone for 14 days Drug: control |
Not Applicable | South Valley University | OTHER | 450 | All | 18 Years | south-Vally University faculty of medicine, Qena, Kena, Egypt |
| 525 | Completed | Short Term, High Dose Vitamin D Supplementation for COVID-19 | COVID | Drug: Vit D | Not Applicable | Postgraduate Institute of Medical Education and Research | OTHER_GOV | 40 | All | 18 Years | Deptt of Endocrinology, Chandigarh, India |
| 524 | Active, not recruiting | Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease | Covid19 | Drug: cholecalciferol 6 lakh IU | Phase 4 | Postgraduate Institute of Medical Education and Research | OTHER_GOV | 90 | All | 18 Years ~ 80 Years | Deptt of Endocrinology, Chandigarh, India |
| 523 | Completed | Sildenafil in COVID-19 | SARS-COV2 Infection | Drug: Sildenafil Drug: Placebo |
Phase 2 | Universidad Nacional Andres Bello, Hospital Naval Almirante Nef, Vina del Mar, Chile | OTHER | 40 | All | 18 Years | Hospital Naval Almirante Nef, Vina Del Mar, Valparaiso, Chile |
| 522 | Recruiting | Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) | Coronavirus | Drug: Silmitasertib | Phase 2 | University of Arizona, Senhwa Biosciences, Inc. | OTHER | 40 | All | 18 Years | Banner University Medical Center Phoenix, Phoenix, Arizona, United States Banner University Medical Center Tucson, Tucson, Arizona, United States |
| 521 | Terminated | SILtuximab in Viral ARds (SILVAR) Study | Respiratory Tract Disease | Drug: Siltuximab Other: Normal Saline |
Phase 3 | EusaPharma (UK) Limited, Syneos Health | INDUSTRY | 555 | All | 12 Years ~ 65 Years | Sparrow Clinical Research Institute, Lansing, Michigan, United States Atrium Health, Charlotte, North Carolina, United States |